We are live on
!
Find out more
CCM
Copernicus Capital Management Portfolio holdings
AUM
$8.26M
1-Year Est. Return
37.91%
This Fund
S&P 500
This Quarter
Est. Return
+12.75%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$39M
AUM Growth
-$14.1M
(-27%)
Cap. Flow
-$18.7M
Cap. Flow
% of AUM
-47.88%
Top 10 Holdings %
Top 10 Hldgs %
88.14%
Holding
18
New
5
Increased
3
Reduced
6
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$4.23M |
| 2 |
UnitedHealth
UNH
|
+$3.06M |
| 3 |
IQVIA
IQV
|
+$2.67M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$1.56M |
| 5 |
Heron Therapeutics
HRTX
|
+$1.12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuitive Surgical
ISRG
|
+$5.33M |
| 2 |
Merck
MRK
|
+$5.23M |
| 3 |
Illumina
ILMN
|
+$4.65M |
| 4 |
CVS Health
CVS
|
+$3.93M |
| 5 |
Gilead Sciences
GILD
|
+$3.86M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Thermo Fisher Scientific
TMO
$213B
| $5.2M | 13.33% |
18,990
-10
| -0.1% | -$2.49K |
|
2
Zoetis
ZTS
$31.3B
| $5.08M | 13.01% |
50,413
+4,974
| +11% | +$452K |
|
|
3
Bristol-Myers Squibb
BMY
$126B
| $4.05M | 10.4% |
+85,000
| New | +$4.23M |
|
|
4
Heron Therapeutics
HRTX
$86.9M
| $3.32M | 8.52% |
135,946
+42,946
| +46% | +$1.12M |
|
5
Vertex Pharmaceuticals
VRTX
$120B
| $3.29M | 8.43% |
17,863
-15,020
| -46% | -$2.77M |
|
|
6
UnitedHealth
UNH
$385B
| $2.97M | 7.61% |
+12,000
| New | +$3.06M |
|
7
Stryker
SYK
$122B
| $2.88M | 7.4% |
14,608
-10,018
| -41% | -$1.8M |
|
|
8
IQVIA
IQV
$34.6B
| $2.88M | 7.38% |
+20,000
| New | +$2.67M |
|
|
9
Gilead Sciences
GILD
$162B
| $2.66M | 6.83% |
40,946
-58,054
| -59% | -$3.86M |
|
10
CareDx
CDNA
$1.94B
| $2.05M | 5.25% |
64,944
+9,968
| +18% | +$290K |
|
|
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $1.74M | 4.47% |
+66,000
| New | +$1.56M |
|
|
12
Illumina
ILMN
$29.8B
| $1.65M | 4.24% |
5,469
-15,942
| -74% | -$4.65M |
|
|
13
Intuitive Surgical
ISRG
$119B
| $914K | 2.34% |
4,806
-30,012
| -86% | -$5.33M |
|
|
NVRO
14
DELISTED
NEVRO CORP.
NVRO
| $313K | 0.8% |
+5,000
| New | +$235K |
|
|
15
CVS Health
CVS
$136B
| – | – |
-59,956
| Closed | -$3.93M |
|
|
16
Merck
MRK
$322B
| – | – |
-71,747
| Closed | -$5.23M |
|
|
AGN
17
DELISTED
Allergan plc
AGN
| – | – |
-15,000
| Closed | -$2M |
|
|
WCG
18
DELISTED
Wellcare Health Plans, Inc.
WCG
| – | – |
-11,500
| Closed | -$2.71M |
|
Similar funds
AAM
IR
YEPV
LC
MA
IFC
PVMCV
ARTA
Copernicus Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Copernicus Capital Management held 18 positions worth $39M, down 27% from $53.1M the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Copernicus Capital Management withdrew a net $18.7M in Q1 2019, closing 4 positions and reducing 6 holdings. Its most notable exit was Merck, an estimated $5.23M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.
Against the trend, Copernicus Capital Management opened a new position in Bristol-Myers Squibb worth $4.05M.
- Copernicus Capital Management's largest Q1 2019 buy was Bristol-Myers Squibb: 85,000 shares worth $4.05M.
- Copernicus Capital Management added most to Heron Therapeutics in Q1 2019, an estimated $1.12M increase.
- Copernicus Capital Management's biggest Q1 2019 reduction was Intuitive Surgical, cutting an estimated $5.33M.
- Copernicus Capital Management fully exited Merck in Q1 2019, selling an estimated $5.23M.
- Copernicus Capital Management's ten largest holdings make up 88% of its $39M portfolio in Q1 2019.
- Copernicus Capital Management opened 5 new positions and closed 4 in Q1 2019.
- Copernicus Capital Management's portfolio value fell 27% quarter-over-quarter to $39M.
Based on Copernicus Capital Management's 13F filing for Q1 2019, filed 15 May 2019.